Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06456580 · ClinicalTrials.gov registry record · Phase 3
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
A Phase 3 study of Generalized Myasthenia Gravis, sponsored by Vor Biopharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06456580 is a Phase 3 study of Generalized Myasthenia Gravis that is actively recruiting participants, run by Vor Biopharma. The registered enrollment target is 180 participants, above the 124-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06456580, a Phase 3 study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by Vor Biopharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Telitacicept
Study Locations (20)
California
- University of Southern California - Los Angeles
- University of California Irvine - Orange
- University of California San Francisco (UCSF) - San Francisco
Florida
- SFM Clinical Research - Boca Raton
- Allied Biomedical Research Institute (ABRI) - Miami
- Medsol Clinical Research Center - Port Charlotte
Kentucky
- University of Kentucky - Lexington
- University of Louisville Physicians - Louisville
Michigan
- Michigan State University Clinical Center - East Lansing
- Trinity Health - Grand Rapids Hospital - Grand Rapids
New York
- Mount Sinai Health System - New York
- Montefiore Medical Center - The Bronx
Texas
- University of Texas Southwestern Medical Center - Dallas
- Houston Methodist Neurological Institute - Houston
Georgia
- Wellstar MCG Health Medical Center - Augusta
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-07-17 |
| Est. Completion | 2029-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06456580
The ClinicalTrials.gov registry entry for NCT06456580 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 124-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (45% higher). The listed sponsor is Vor Biopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06456580 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06456580 about?
NCT06456580 is a clinical study titled "A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)". The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.
What is the current status of trial NCT06456580?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2024-07-17. Estimated completion is 2029-01.
What conditions does trial NCT06456580 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT06456580?
The interventions under investigation include: Placebo (DRUG), Telitacicept (BIOLOGICAL).
Who is sponsoring clinical trial NCT06456580?
This trial is sponsored by Vor Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06456580 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.